Key terms
About NVRO
Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NVRO news
Apr 11
7:03am ET
Nevro price target lowered to $16 from $20 at Mizuho
Apr 08
5:31am ET
Nevro price target lowered to $14 from $17 at Wells Fargo
Apr 03
5:52am ET
Nevro price target lowered to $16 from $18 at Citi
Feb 28
4:11pm ET
Nevro says FDA clears sacroiliac joint fusion device, Nevro1
Feb 26
9:30pm ET
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
Feb 25
11:58pm ET
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
Feb 22
8:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Silver Spike Investment (SSIC) and Ionis Pharmaceuticals (IONS)
Feb 22
7:34am ET
RBC Capital Sticks to Their Hold Rating for Nevro Corp (NVRO)
Feb 22
7:22am ET
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
Feb 22
7:19am ET
Nevro downgraded to Perform from Outperform at Oppenheimer
Feb 22
7:01am ET
Nevro price target lowered to $17 from $20 at Wells Fargo
Feb 22
6:50am ET
Nevro price target lowered to $19 from $23 at Baird
Feb 22
12:26am ET
Nevro Corp: A Buy Rating with a Positive Outlook on Financial Stability and Strategic Growth
Feb 21
4:25pm ET
Nevro enters cooperation agreement with Engaged Capital
Feb 21
4:23pm ET
Nevro Corp Enhances Board and Governance with New Director Appointment
Feb 21
4:23pm ET
Nevro sees Q1 revenue up 1%-3% y-o-y to $97M-$99M, consensus $98.72M
Feb 21
4:22pm ET
Nevro Sees FY24 revenue up 2%-5% to $435M-$445M, consensus $444.54M
Jan 30
9:25pm ET
Truist Financial Reaffirms Their Hold Rating on Nevro Corp (NVRO)
Jan 22
7:03am ET
Nevro price target lowered to $19 from $23 at Canaccord
Jan 18
4:21pm ET
Nevro announces Carelon publication on new interventional pain management policy
No recent news articles are available for NVRO
No recent press releases are available for NVRO
NVRO Financials
Key terms
Ad Feedback
NVRO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NVRO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
